TradeFlare's AI research teams analysed SMMT on 5 market nights between June 5, 2026 and September 11, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 11, 2026 | BUY | $17.00 | $24.65 / $14.45 | +1.7% | +0.2% | The post-earnings drift signal suggests a multi-week opportunity driven by fundamental catalysts. |
| September 10, 2026 | HOLD | $17.54 | — / — | +4.2% | +1.0% | The stock's current technical and fundamental outlook does not support a buy recommendation. |
| September 9, 2026 | BUY | $17.28 | $20.74 / $14.69 | -1.4% | +2.3% | The post-earnings drift signal suggests a multi-week trend. |
| June 15, 2026 | BUY | $14.01 | — / — | +0.8% | +6.7% | The market regime is neutral, and the stock has multiple bearish indicators that outweigh the insider buying signal. |
| June 5, 2026 | BUY | $14.84 | — / — | -5.2% | +7.5% | Positive clinical trial data for ivonescimab. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.